Effect of the Prebiotic Oligofructose on Relapse of Clostridium difficile-Associated Diarrhea: A Randomized, Controlled Study

Published:February 15, 2005DOI:
      Background & Aims: Ten percent to 20% of patients relapse after successful treatment of their Clostridium difficile-associated diarrhea. We set out to determine if the prebiotic oligofructose could alter the fecal bacterial flora and, in addition to antibiotic treatment, reduce the rate of relapse from C difficile infection. Methods: Consecutive inpatients with C difficile-associated diarrhea were randomly allocated to receive oligofructose or placebo for 30 days in addition to specific antibiotic treatment. Patients were followed up for an additional 30 days. The main end point was the development of further diarrhea. Stools were collected for bacterial culture and C difficile toxin measurement. Results: One hundred forty-two patients were recruited. Stool culture confirmed the probiotic effect of oligofructose with an increase in fecal bifidobacteria from baseline 8.68 log10 colony-forming units (cfu)/g to 9.37 log10 cfu/g at discharge (P < .0001; 95% confidence interval [CI], 0.45–0.94), 9.64 log10 cfu/g at 30 days (P < .0001; 95% CI, 0.74–1.18), and 9.42 log10 cfu/g at 60 days (P < .0001; 95% CI, 0.56–0.93). Thirty patients experienced a relapse of diarrhea after a median of 18 days (range, 8–34 days). Relapse of diarrhea was more common in those taking placebo (8.3% oligofructose vs 34.3% placebo, P < .001, χ2 = 14.35). Patients who relapsed stayed in the hospital longer than those who did not (53 vs 26 days, P = .021; 95% CI, 2–28), and there was a longer period of time from commencing metronidazole or vancomycin and their diarrhea settling (6 vs 3 days; P = .007; 95% CI, 1.0–5.0). Conclusions: Fecal cultures confirmed the prebiotic effect of oligofructose. Patients taking oligofructose were less likely to develop further diarrhea than those taking the placebo.

      Abbreviations used in this paper:

      CFU (colony-forming unit), CI (confidence interval)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Larson H.E.
        • Borriello S.P.
        Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters.
        Antimicrob Agents Chemother. 1990; 34: 1348-1353
        • Borriello S.P.
        • Barclay F.E.
        An in-vitro model of colonisation resistance to clostridium difficile infection.
        J Med Microbiol. 1986; 21: 299-309
        • Thomas D.R.
        • Bennett R.G.
        • Laughon B.E.
        • et al.
        Postantibiotic colonization with Clostridium difficile in nursing home patients.
        J Am Geriatr Soc. 1990; 38: 415-420
        • McFarland L.V.
        • Surawicz C.M.
        • Stamm W.E.
        Risk factors for Clostridium difficile carriage and C difficile-associated diarrhea in a cohort of hospitalized patients.
        J Infect Dis. 1990; 162: 678-684
        • Bender B.S.
        • Laughon B.E.
        • Gaydos C.
        Is Clostridium difficle endemic in chronic-care facilities?.
        Lancet. 1986; ii: 11-13
        • Kelly C.P.
        • Pothoulakis C.
        • Lamont J.T.
        Clostridium difficile colitis.
        N Engl J Med. 1994; 330: 257-262
        • Bullen C.L.
        • Willis A.T.
        Resistance of the breast-fed infant to gastro-enteritis.
        Br Med J. 1971; 3: 338-343
        • Wang X.
        • Gibson G.R.
        Effects of in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine.
        J Appl Bacteriol. 1993; 75: 373-380
        • Gibson G.R.
        • Wang X.
        Regulatory effects of bifidobacteria on the growth of colonic bacteria.
        J Appl Bacteriol. 1994; 77: 412-420
        • Marteau P.
        • Pochart P.
        • Flourie B.
        • et al.
        Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans.
        Am J Clin Nutr. 1990; 52: 685-688
        • Wells C.L.
        • Maddaus L.A.
        • Jechorek R.P.
        • et al.
        Role of intestinal anaerobic bacteria in colonisation resistance.
        Eur J Clin Microbiol Infect Dis. 1988; 7: 107-113
        • Yamazaki S.
        • Kamimura H.
        • Momose H.
        • et al.
        Protective effect of Bifidobacterium monoassociation against lethal activity of E Coli.
        Bifidobacteria Microflora. 1982; 1: 55-60
        • Molis C.
        • Flourié B.
        • Ouarne F.
        • et al.
        Digestion, excretion, and energy value of fructooligosaccharides in healthy humans.
        Am J Clin Nutr. 1996; 64: 324-328
        • Gibson G.R.
        • Beatty E.R.
        • Wang X.
        • et al.
        Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin.
        Gastroenterology. 1995; 108: 975-982
        • Wolf B.W.
        • Meulbroek J.A.
        • Jarvis K.P.
        • et al.
        Dietary supplementation with fructooligosaccharides increases survival time in a hamster model of Clostridium difficile-colitis.
        Bioscience Microflora. 1997; 16: 59-64
        • Beerens H.
        An elective and selective isolation medium for Bifidobacterium spp.
        Lett Appl Microbiol. 1990; 11: 155-157
        • Brazier J.S.
        The diagnosis of Clostridium difficile associated disease.
        J Antimicrob Chemother. 1998; 41: 29-40
        • Fekety R.
        • McFarland L.V.
        • Surawicz C.M.
        • et al.
        Recurrent Clostridium difficile diarrhea.
        Clin Infect Dis. 1997; 24: 324-333
        • Bovee-Oudenhoven I.M.J.
        • Bruggencate J.J.M.
        • Lettink-Wissink M.L.G.
        • et al.
        Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of salmonella in rats.
        Gut. 2003; 52: 1572-1578
        • Johnson S.
        • Adelmann A.
        • Clabots C.R.
        • et al.
        Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism.
        J Infect Dis. 1989; 159: 340-343
        • McFarland L.V.
        • Surawicz C.M.
        • Rubin M.
        Recurrent Clostridium difficile disease.
        Infect Control Hosp Epidemiol. 1999; 20: 43-50
        • Gerding D.N.
        Treatment of Clostridium difficile-associated diarrhea and colitis.
        Curr Top Microbiol Immunol. 2000; 250: 127-139
        • McFarland L.V.
        • Surawicz C.M.
        • Greenburg R.N.
        • et al.
        A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.
        JAMA. 1994; 271: 1913-1918
        • Grillot R.
        • Lebeau B.
        • Goullier-Fleuret A.
        • et al.
        “De deux maux il faut choiser le mondre” ou du caractere opportuniste de Saccharomyces boulardii.
        Royal Société Française de Mycologie Médicale, Paris1986
        • Zunic P.
        • Lacotte J.
        • Pegoix M.
        • et al.
        Fongémie a Saccharomyces boulardii.
        Therapie. 1991; 46: 498-499